Association of influenza vaccination with reduced risk of venous thromboembolism
Abstract number: OC-WE-017
Emmerich1 J., Zhu1 T., Carcaillon2 L., Martinez1 I., Cambou3 J., Kyndt4 X., Guillot5 K., Vergnes6 M., Scarabin2 P.
11INSERM U765, University Paris Descartes, Paris 22INSERM U780, INSERM, Villejuif 33Department of vascular medicine, CHU Rangueil, Toulouse 44Department of Internal Medicine-Nephrology, Centre Hospitalier de Valenciennes, Valenciennes 55CHU de Saint Etienne, H˘pital belleveue, Saint Etienne 66Department of Hematology, H˘pital Cardiologique, Pessac, France
How-to-cite Emmerich J, Zhu T, Carcaillon L, Martinez I, Cambou J, Kyndt X, Guillot K, Vergnes M, Scarabin P. Association of influenza vaccination with reduced risk of venous thromboembolism. Journal of Thrombosis and Haemostasis 2009; Volume 7, Supplement 2: Abstract OC-WE-017
Introduction: Influenza vaccination can reduce the risk of cardiovascular events in patients with coronary heart disease, but its impact on the risk of venous thromboembolism (VTE) has not been studied.
Methods: We conducted a case-control study involving 1454 adults enrolled in 11 French centers between 2003 and 2007, comprising 727 consecutive cases with a first documented episode of VTE and 727 age- and sex-matched controls.
Results: In the case and control groups respectively 202 (28.2%) and 233 (32.1%) subjects had been vaccinated against influenza during the previous 12 months. After multivariate regression analysis, the odds ratios (OR) for VTE associated with vaccination were 0.74 (95% confidence interval [CI], 0.57–0.97) and 0.52 (95% CI, 0.32–0.85), respectively, for the whole population and for subjects aged 52 years or less. The protective effect of vaccination was similar for deep venous thrombosis (OR 0.9; 95% CI, 0.60–1.35) and pulmonary embolism (OR 0.71; 95% CI, 0.53–0.94) and for both provoked (OR 0.71; 95% CI, 0.53–0.97) and unprovoked VTE (OR 0.85; 95% CI, 0.59–1.23).
Conclusions: This case-control study suggests that influenza vaccination is associated with a reduced risk of venous thromboembolism.
Disclosure of interest: none declared.